A PHP Error was encountered

Severity: Warning

Message: fopen(/var/cpanel/php/sessions/ea-php74/ci_session9271576a10c3bb0663ac1f2aad44340f28e6bf5e): failed to open stream: No space left on device

Filename: drivers/Session_files_driver.php

Line Number: 176

Backtrace:

File: /home/drugtodayonline/public_html/application/controllers/Medical_news.php
Line: 9
Function: __construct

File: /home/drugtodayonline/public_html/index.php
Line: 311
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: session_start(): Failed to read session data: user (path: /var/cpanel/php/sessions/ea-php74)

Filename: Session/Session.php

Line Number: 143

Backtrace:

File: /home/drugtodayonline/public_html/application/controllers/Medical_news.php
Line: 9
Function: __construct

File: /home/drugtodayonline/public_html/index.php
Line: 311
Function: require_once

Bayer and Mammoth Biosciences to Collaborate on Novel Gene Editing Technology

Look for Drugs and Conditions

Reference pic

Bayer and Mammoth Biosciences to Collaborate on Novel Gene Editing Technology

DTMT Network

Bayer AG and Mammoth Biosciences, Inc. have announced a strategic collaboration and option agreement for the use of Mammoth’s CRISPR systems to develop in vivo gene-editing therapies, on January 10, 2022.

Mammoth Biosciences’ gene-editing technology is considered to be a key enabling technology, as well as a stand-alone therapeutic modality. It is expected to significantly enhance Bayer’s efforts to develop transformative therapies for patients faster and strengthen the company’s recently established new cell and gene therapy platform, analysts say.

“Bringing together Mammoth’s novel CRISPR systems with our existing gene augmentation and our induced pluripotent stem cell (iPSC) platforms will allow us to unleash the full potential of our cell and gene therapy strategy,” said Stefan Oelrich, Member of the Board of Management, Bayer AG and President of the Bayer’s Pharmaceuticals Division.

“Partnering with Mammoth’s cutting edge scientific team is a fundamental pillar for our company to improve the lives of patients suffering from conditions that are currently still difficult to treat,” he added.

“We’re excited to be working together with Bayer, building on the technology leap of our novel CRISPR systems, along with Bayer’s expertise in successful drug development,” said Dr Peter Nell, Chief Business Officer and Head of Therapeutic Strategy at Mammoth.

“This joint effort has the potential to benefit patients by developing CRISPR-based approaches for the clinic with the appropriate urgency while ensuring scientific excellence and safety,” Dr Neil added.

Under the terms of the agreement, the two companies will start their collaboration with a focus on liver-targeted diseases, the announcement said.

Mammoth Biosciences will receive a 40 million USD and will be eligible to receive target option exercise fees as well as potential future payments in the magnitude of more than one billion USD upon successful achievement of certain research, development, and commercial milestones across five preselected in vivo indications with the first focus on liver-targeted diseases, a statement released by the company said.

In addition, Bayer will pay research funding and tiered royalties up to a low double-digit percentage of net sales. The companies are also exploring work on ex vivo projects on a nonexclusive basis, the statement added.


0 Comments
Be first to post your comments

Post your comment

Related Articles

A PHP Error was encountered

Severity: Warning

Message: mysqli::query(): (HY000/1): Can't create/write to file '/tmp/#sql_3cd_0.MYI' (Errcode: 28 - No space left on device)

Filename: mysqli/mysqli_driver.php

Line Number: 307

Backtrace:

File: /home/drugtodayonline/public_html/application/models/Site_ads_model.php
Line: 118
Function: query

File: /home/drugtodayonline/public_html/application/libraries/Common_lib.php
Line: 318
Function: get_front_ads_data

File: /home/drugtodayonline/public_html/application/views/front/news_topic.php
Line: 332
Function: common_footer_ads

File: /home/drugtodayonline/public_html/application/controllers/Medical_news.php
Line: 361
Function: view

File: /home/drugtodayonline/public_html/application/controllers/Medical_news.php
Line: 28
Function: news_topic

File: /home/drugtodayonline/public_html/index.php
Line: 311
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Cannot modify header information - headers already sent by (output started at /home/drugtodayonline/public_html/system/core/Exceptions.php:271)

Filename: core/Common.php

Line Number: 570

Backtrace:

File: /home/drugtodayonline/public_html/application/models/Site_ads_model.php
Line: 118
Function: query

File: /home/drugtodayonline/public_html/application/libraries/Common_lib.php
Line: 318
Function: get_front_ads_data

File: /home/drugtodayonline/public_html/application/views/front/news_topic.php
Line: 332
Function: common_footer_ads

File: /home/drugtodayonline/public_html/application/controllers/Medical_news.php
Line: 361
Function: view

File: /home/drugtodayonline/public_html/application/controllers/Medical_news.php
Line: 28
Function: news_topic

File: /home/drugtodayonline/public_html/index.php
Line: 311
Function: require_once

Database Error

A Database Error Occurred

Error Number: 1

Can't create/write to file '/tmp/#sql_3cd_0.MYI' (Errcode: 28 - No space left on device)

SELECT * FROM `dt_site_ads` WHERE `status` = '1' and `loc` = 'pre_footer_4' ORDER BY RAND() LIMIT 0,1

Filename: models/Site_ads_model.php

Line Number: 118